Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform

The overall aim of this proposed research is to determine the safety, feasibility and efficacy (AP vs at home use of SAP) of the Diabetes Assistant (DiAs) controller in day and night closed-loop control in young children 5-8 years old with type 1 diabetes over multiple 48 hours in an out-patient setting.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 1
• Intervention / Treatment: Device: Diabetes Assistant (DiAs) with Closed-Loop

Detailed Description

Young children with Type 1 Diabetes (T1D) in the age range of 5-8 years old are a population with clear needs but unique challenges regarding the application of artificial pancreas (AP) technologies. Young children are likely to benefit from an AP system, with current deficits in glycemic control that include both significant hypoglycemia and sub-optimal HbA1c levels; however, they have undeveloped abilities to control and interact with the AP system, posing potential safety issues. During the hours that these children are away from their parents at school and elsewhere, they lack the sophistication to operate the currently-available tools in an AP system--and may induce harm if they are allowed to do so, causing parental resistance to AP use. Commercially-available insulin pumps have mechanisms to lock access to children to prevent inappropriate insulin-delivery. However, the AP is more complex than an insulin pump, both in requiring more detailed setting information (that a child could adversely alter) and in providing alerts for impending low- and high-blood glucose (BG) levels (that one wouldn't want to lock out to child use). These functions are all run via a platform on a smart phone-a device with which young children may already feel a high degree of familiarity and thus be more likely to attempt to explore and potentially change settings. It is likely that young children will benefit the most from a system that gives them access to some AP features but provides access to other features only for their parents. In this sense, young children require a device that is not user-centered as much as family-centered. A redesign of the system to provide appropriate access to AP tools-in which certain users can obtain access to certain functionalities-is direly needed before children in this age range can benefit from the improvements in blood glucose (BG) control that the AP has to offer.

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • University of Virginia Center for Diabetes Technology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 5 years to 9 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Clinical diagnosis of type 1 diabetes,

  • The diagnosis of type 1 diabetes is based on the investigator's judgment
  • C peptide levels and antibody determinations are not required
• Daily insulin therapy for ≥ 12 months
• Insulin pump therapy for ≥ 3 months
• Age ≥5 - ≤8 years old
• Avoidance of acetaminophen-containing medications (i.e. Tylenol) while wearing the continuous glucose monitor.
• Willingness to wear a continuous glucose sensor and physiological monitor for the duration of the study

Exclusion Criteria:

The presence of any of the following is an exclusion for the study:

• Diabetic ketoacidosis in the past month
• Hypoglycemic seizure or loss of consciousness in the past 3 months
• History of seizure disorder (except for hypoglycemic seizure)
• History of any heart disease including coronary artery disease, heart failure, or arrhythmias
• Cystic fibrosis
• Current use of oral glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.
• History of ongoing renal disease (other than microalbuminuria).
• Subjects requiring intermediate or long-acting insulin (such as NPH, Detemir or Glargine).
• Subjects requiring other anti-diabetic medications other than insulin (oral or injectable).
• Presence of a febrile illness within 24 hours of admission or acetaminophen use while wearing the CGM. The subject may be rescheduled for Research House/Hotel Admission if these criteria are not met. The study subject will not participate in the trial if these conditions are met.

• Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as:

  • Inpatient psychiatric treatment in the past 6 months
  • Uncontrolled adrenal insufficiency

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A; In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.	Device: Diabetes Assistant (DiAs) with Closed-Loop; All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
Experimental: Group B; Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.	Device: Diabetes Assistant (DiAs) with Closed-Loop; All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of Sensor Glucose Readings Between 70-180 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	68 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of Time Sensor Glucose Readings Are <70 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	68 hours
Percent of Time Sensor Glucose Readings Are >150 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Percent of Time Sensor Glucose Readings Are >180 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	68 hours
Percent of Time Sensor Glucose Readings Are >250 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	68 hours
Percent of Time Sensor Glucose Readings Are >400 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Distribution of Sensor and Meter Glucose Values (Maximum, Minimum, Median, Interquartile Range, Mean, Standard Deviation)	All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Distribution of Sensor and Meter Glucose Values (Maximum)	All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Distribution of Sensor and Meter Glucose Values (Minimum)	All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Distribution of Sensor and Meter Glucose Values (Median/Interquartile Range)	All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Mean BG (as Measured by CGM)	All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.	68 hours
Hypoglycemia Area Under the Curve <60	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Hypoglycemia Area Under the Curve <70 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Hyperglycemia Area Under the Curve >180	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Hyperglycemia Area Under the Curve >250 mg/dL	All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.	72 hours
Incidence of Hypoglycemia Per Subject, Defined by Handheld Meter Glucose <70 mg/dL	All subjects have hypoglycemia monitored by meter analysis and compared between time on closed-loop system and time on usual care period.	68 hours
End of Night Blood Glucose	All subjects have blood glucose evaluated upon rising (approximately 7 am) and compared between time on closed-loop system and time on usual care period.	72 hours

Collaborators and Investigators

• Sponsor: University of Virginia
• Collaborators: DexCom, Inc.
• Investigators: Principal Investigator: Mark D. DeBoer, MD, University of Virginia, Pediatrics, Endocrinology/Diabetes

Publications and helpful links

General Publications

• DeBoer MD, Breton MD, Wakeman C, Schertz EM, Emory EG, Robic JL, Kollar LL, Kovatchev BP, Chernavvsky DR. Performance of an Artificial Pancreas System for Young Children with Type 1 Diabetes. Diabetes Technol Ther. 2017 May;19(5):293-298. doi: 10.1089/dia.2016.0424. Epub 2017 Apr 20.

Helpful Links

• Use of an AP in young children was safe and resulted in improved mean BG without increased hypoglycemia. This suggests that AP use in young children is safe and improves overall diabetes control.

Study record dates

Study Major Dates

• Study Start: May 1, 2016
• Primary Completion (Actual): May 1, 2016
• Study Completion (Actual): May 1, 2016

Study Registration Dates

• First Submitted: April 15, 2016
• First Submitted That Met QC Criteria: April 20, 2016
• First Posted (Estimate): April 25, 2016

Study Record Updates

• Last Update Posted (Actual): July 24, 2017
• Last Update Submitted That Met QC Criteria: June 22, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Keywords: Pediatric; Insulin Pump; Closed-Loop Control (CLC); Continuous Glucose Monitor; Type 1 Diabetes Mellitus (T1DM); Artificial Pancreas Project (APP); Diabetes Assistant (DiAs)
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1
• Other Study ID Numbers: 18888

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Not yet determined